3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
Rituximab
45
Cyclophosphamide
32
Lenalidomide
24
fludarabine
20
zanubrutinib
13
venetoclax
12
obinutuzumab
12
orelabrutinib
11
fludarabine phosphate
10
Bendamustine Hydrochloride
10
Magnetic Resonance Spectroscopy
9
Whole-Body Irradiation
8
Prednisone
8
pirtobrutinib
7
ibrutinib
7
Vincristine
7
Specimen Handling
7
CT-P10
7
Mycophenolic Acid
6
Biopsy
6
Doxorubicin
5
tafasitamab
4
pembrolizumab
3
acalabrutinib
3
Tacrolimus
3
Sirolimus
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Melphalan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
CLR1404
×
1 year
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled